BIOFIRE Defense, LLC Test Kits and Reagents
ID: 25-000958-1Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/1e7afe0348c04097b5fc6f17a605ca6d/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a fixed-price contract to BioFire Defense, LLC for the provision of BIOFIRE® Reagent Kits and associated test kits. The procurement aims to secure proprietary test kits and reagents essential for the NIH Clinical Center's Department of Laboratory Medicine, which supports patient care and research by detecting pathogens in various patient specimens, including blood and respiratory samples. The BioFire test kits are critical for rapid diagnostics, allowing clinicians to initiate timely treatment for infections, and BioFire Defense, LLC is the sole source for these products due to compatibility requirements with government-owned analyzers. Interested parties capable of providing similar products may submit capability statements by November 17, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov.

    Point(s) of Contact
    Sheri Eiri
    000000000
    sheri.eiri@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    BIOFIRE Defense, LLC Test Kits and Reagents
    Currently viewing
    Presolicitation
    Similar Opportunities
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    Lab Reagents for Pathology Dept. at WRNMMC
    Active
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award a sole source contract to Roche Diagnostics Corporation for the procurement of specialized lab reagents and consumables necessary for molecular diagnostics testing in the Pathology Department at Walter Reed National Military Medical Center (WRNMMC). This procurement is critical for testing viral pathogens and is supported under the authority for non-competitive purchases, as Roche is the sole supplier of the proprietary materials required for use with the existing Roche medical equipment at WRNMMC. Interested parties may submit their qualifications by January 10, 2025, via email to the primary contact, Ealed Nuru, at ealed.m.nuru.civ@health.mil, with a copy to Erica S. Oh at erica.s.oh.civ@health.mil. The government retains discretion over the contract award process and is not obligated to seek competitive bids despite any expressions of interest received.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.
    Nova Benchtop System
    Active
    Dept Of Defense
    The Department of Defense, through the United States Army Medical Research Acquisition Activity (USAMRAA), intends to negotiate a sole source contract with Helix Biotech for the acquisition of a Nova Benchtop Microfluidics device. This procurement aims to secure a chip-less, scalable, and highly flexible modular system essential for the encapsulation of mRNA for cellular delivery, including all necessary ancillary components, delivery, self-installation with virtual support, training, and a one-year manufacturer warranty. The device is critical for producing lipid nanoparticles, which play a significant role in various biomedical applications. Interested parties may submit their capability information by 2:00 p.m. Eastern Time on January 16, 2025, to Ms. Natalie Bethel at natalie.l.bethel2.civ@health.mil, as this notice is not a request for competitive quotations.
    Ongoing Monoclonal Antibodies and Plasmids Services through GENSCRIPT
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with GenScript USA Inc. for ongoing monoclonal antibodies and plasmids services. The procurement aims to support the NIAID Laboratory of Immunogenetics (LIG) in advancing research on human B cells and the isolation of monoclonal antibodies, which are critical for developing new vaccine candidates against influenza. This contract is a continuation of existing services that require continuity for accurate comparison of results, and interested parties may submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET. For further inquiries, contact Dana Monroe at dana.monroe@nih.gov or call 406-375-9814.
    Orbitor RS2 Microplate Robotic Bundle with Software
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through its National Institute of Allergy and Infectious Diseases (NIAID), intends to procure an Orbitor RS2 Microplate Robotic Bundle with integrated software for its Vaccine Immunology Program (VIP) within the Vaccine Research Center (VRC). This procurement aims to automate the handling and analysis of Mabtech Fluorospot Assays, which are critical for evaluating T-cell responses in clinical trials, thereby enhancing the efficiency and accuracy of vaccine research. The equipment must meet specific technical requirements, including compatibility with existing lab systems and advanced features such as a bi-directional telescoping arm and Momentum™ scheduling software. Interested vendors are invited to submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET, with all submissions considered by the Government at its discretion.
    Microbial Testing Supplies - Bridge Contract
    Active
    Dept Of Defense
    The Department of Defense, specifically the Department of the Army, is seeking to award a sole-source bridge contract for microbial testing supplies to Biomerieux Inc., covering the period from October 1, 2024, to September 30, 2025. This procurement is essential for the William Beaumont Army Medical Center Laboratory, as it involves leasing a microbial identification analyzer and a mass spectrometer, along with necessary reagents and middleware/server interface provision. The unique requirements for ATO authorization on DHA networks necessitate this sole-source approach, as Biomerieux is the only contractor capable of meeting these needs without service disruption. Interested parties can contact Troy Loge at troy.a.loge.civ@health.mil or Robyn Villafranco at Robyn.A.Villafranco.civ@health.mil for further details, with the total contract value estimated at $213,334.67.
    CDC DFWED NARST Sensititre Supplies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking to award a sole source contract for antimicrobial resistance testing supplies, specifically Sensititre™ broth microdilution testing products, from ThermoFisher Scientific. This procurement is essential for the National Antimicrobial Resistance Monitoring System (NARMS), which has utilized these proprietary materials since 1996 to ensure a standardized approach to monitoring enteric bacteria resistance. The unique nature of these supplies necessitates this sole source approach, as alternatives would require significant investments in new equipment and validation processes, potentially disrupting critical surveillance efforts. Interested parties may respond within 15 days to express their interest, with proposals directed to contract specialist Ashley Williams at dal3@cdc.gov.
    Sources Sought Notice - Cost-Per-Test (CPT) Agreement or Reagent Rental Agreement to include reagents, molecular PCR instrument/equipment, consumables, maintenance support and instrument warranties at BAMC.
    Active
    Dept Of Defense
    The Department of Defense, through the Medical Readiness Contracting Office West (MRCO), is seeking potential sources for a Cost-Per-Test (CPT) Agreement or Reagent Rental Agreement to support molecular genetic and infectious disease testing at the Brooke Army Medical Center (BAMC) in Fort Cavazos, Texas. The procurement includes the provision of molecular PCR instruments, reagents, consumables, maintenance support, and instrument warranties, with a base performance period from October 1, 2025, to September 30, 2030. This initiative is critical for enhancing the laboratory's capabilities in conducting various genetic tests, including those for Celiac Disease, Alzheimer’s Disease, and a comprehensive Dermatomycosis Panel, which are essential for informed health assessments and treatment decisions. Interested parties are encouraged to submit their capability statements and relevant information to the primary contact, Medina L. Woodson, at medina.l.woodson.civ@health.mil, by the specified deadlines, as this notice is solely for information and planning purposes and does not constitute a solicitation.
    Notice of Intent to Sole Source – TheraDoc subscription
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) Clinical Center intends to award a firm fixed-price purchase order for subscription services related to the TheraDoc application, exclusively owned by Premier Healthcare LLC. This procurement aims to secure applications, support, maintenance, and training for the TheraDoc clinical surveillance solution, which is critical for enhancing healthcare delivery and patient safety. The acquisition will follow the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for a sole-source solicitation due to the unique nature of the services required. Interested parties may express their capabilities and submit comments to the NIH by November 21, 2024, with inquiries directed to Ryssa Nix at Ryssa.nix@nih.gov.